Associate Professor Rachel Conyers
A/Prof Rachel Conyers is a clinician scientist who trained in Paediatric Oncology with specialisation in leukaemia, lymphoma and bone marrow transplantation. She is the current clinical lead of Bone Marrow Transplantation at The Royal Children’s Hospital, Melbourne; and the Team Leader of Pharmacogenomics and recipient of Clinician Scientist Fellowship at Murdoch Children’s Research Institute. She is a recognised national leader in pharmacogenomics and rare toxicities as demonstrated by her position as the lead for Pharmacogenomics implementation and discovery through the Victorian Paediatric Cancer Consortium (VPCC) and co-chair of pharmacogenomics working group in the Zero Childhood Cancer Program.
In 2016 A/Prof Conyers was awarded a Clinician Scientist Fellowship within Murdoch Children’s Research Institute (MCRI) to further her combined clinical and laboratory work in susceptibility to anthracycline toxicity within the Cardiac Regeneration laboratory together with A/Prof David Elliott. A/Prof Conyers’ research focus is on the late effects of therapy, particularly anthracycline cardiomyopathy. The scope of her research includes creating functional models for cardiotoxicity, genomic analysis and acquisition of appropriate patient cohorts and she is the co-founder of the Australian Cardio-Oncology Registry which opened nationally from February 2019.
A/Prof Conyers has further developed her leadership skills by studies at Melbourne Business School Leadership in Health Care (Scholarship Recipient Victorian Comprehensive Cancer Centre), participation in a Masters of Business Administration (MBA) at Melbourne Business School with a Deans Commendation (Business Strategy, 2021), and completion of the Royal Australasian College of Medical Administration Leadership for Clinicians Program (2021, AFRACMA).